LogicBio Therapeutics
Kendall Square
Cambridge
Massachusetts
United States
Tel: 781-771-5579
Website: http://www.logicbio.com/
Email: contact@logicbio.com
About LogicBio Therapeutics
A preclinical-stage company with a mission to develop cures for life-threatening diseases, LogicBio combines the best of gene therapy and genome-editing technology. Founded by gene-therapy pioneers from leading academic institutions including Stanford University, Tel Aviv University, and Children’s Medical Research Institute in Sydney – the company’s core platform includes its proprietary GeneRide technology and synthetic gene-therapy vectors derived from naturally occurring human adeno-associated viruses. LogicBio designed its approach to harness the natural power of homologous recombination - enabling precise, site-specific transfer of the genetic material without the use of promoters or nucleases, which could be associated with unwanted side effects. The goal: provide patients with a functional version of a faulty, disease-causing gene to deliver a cure. LogicBio is advancing programs for rare, life-threatening pediatric genetic diseases - focusing first on inborn errors of metabolism, where there are few, if any, treatment options. A number of the company’s discoveries have been featured in leading science publications and conferences. A private company, LogicBio is based in Cambridge, Massachusetts, with a research group in Tel Aviv.YEAR FOUNDED:
August 2015
LEADERSHIP:
Founders: Adi Barzel Ph.D., Mark Kay M.D. Ph.D. and Leszek Lisowski Ph.D.
President & CEO: Frederic Chereau
61 articles with LogicBio Therapeutics
-
LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia
6/2/2021
Company remains on track to announce update on enrollment, dose escalation and age de-escalation in late 2021 and interim data by year-end 2021
-
LogicBio Therapeutics to Participate in Upcoming Investor Conferences
6/1/2021
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced that Frederic Chereau, chief executive officer of LogicBio, will participate in virtual fireside chats at the following upcoming investor conferences
-
BioSpace Movers & Shakers, May 21
5/21/2021
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers. -
LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership Appointments
5/19/2021
- Stephen Boyer joined company as vice president, regulatory and quality affairs and Peter Pechan joined as vice president, gene therapy
-
BioSpace Movers & Shakers, May 14
5/14/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with Movers & Shakers. -
LogicBio Therapeutics Reports First Quarter Year 2021 Financial Results and Provides Business Update
5/10/2021
- First patient for Phase 1/2 SUNRISE trial expected to be enrolled by mid-year 2021 - Business Development Deals signed with Daichi-Sankyo and CANbridge Pharmaceuticals - New members recently added to Leadership Team
-
LogicBio Therapeutics Strengthens Management Team with Key Appointments
5/10/2021
New leadership includes Andrea Paul as general counsel and corporate secretary, and Janice Olson as senior vice president, strategy and portfolio management, bringing extensive experience in gene therapy and rare disease
-
LogicBio Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
5/4/2021
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced several preclinical data presentations, including an oral presentation, will be delivered at the 24th Annual American Society of Gene and Cell Therapy (ASGCT) Virtual Meeting
-
LogicBio Announces Presentation of Retrospective Study of Disease Course in Pediatric Patients with Severe Methylmalonic Acidemia
5/3/2021
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced results from a retrospective study of the disease course in pediatric patients living with severe methylmalonic acidemia
-
LogicBio Therapeutics Announces Strategic Collaboration and Option Agreement with CANbridge Pharmaceuticals Leveraging Gene Editing and Gene Delivery Platforms
4/27/2021
- LogicBio grants exclusive option to license LB-001 in Greater China; investigational treatment for methylmalonic acidemia based on GeneRide™ platform - Deal also grants worldwide license for AAV sL65, the first capsid based on LogicBio proprietary sAAVyTM platform, to support development of CANbridge gene therapy programs for Fabry disease, Pompe disease and options for two additional indications
-
LogicBio Therapeutics Announces Research Collaboration with Daiichi Sankyo
4/27/2021
- Under the terms of the research collaboration and exclusive option agreement, the companies will initiate a gene editing research program dedicated to the treatment of two early onset indications with high unmet need, leveraging the GeneRide™ platform -
-
LogicBio Therapeutics Announces Clinical and Corporate Updates
4/27/2021
- First patient for Phase I/II SUNRISE trial expected to be enrolled by mid-year 2021 - Company also entered into strategic collaboration with CANbridge Pharmaceuticals and research partnership with Daiichi Sankyo
-
CANbridge Pharmaceuticals Announces Strategic Collaboration with LogicBio Therapeutics and Licenses to Gene Delivery and Editing Platforms
4/27/2021
Worldwide License to AAV sL65 Capsid, Novel Liver-Targeting Capsid, to Support Development of CANbridge Gene Therapy Programs for Fabry disease, Pompe disease and Options for two Additional Indications Option to Exclusive License for LB-001, Investigational Gene Editing Treatment for Methylmalonic Acidemia, in Greater China
-
LogicBio Therapeutics to Present at 2021 Redburn Gene Therapy Summit
3/30/2021
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced that chief executive officer Frederic Chereau will be participating on a panel at the 2021 Redburn Gene Therapy Summit.
-
LogicBio Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update
3/15/2021
- First patient for Phase 1/2 SUNRISE trial expected to be enrolled in early 2021 -Translational preclinical data for sAAVy platform shows substantial improvements over liver tropic capsids used in gene therapy programs to date -New Chief Scientific and Chief Financial Officers recently added to Executive Team
-
LogicBio Announces Extension Of Collaboration With Children's Medical Research Institute
1/7/2021
Collaboration seeks to develop next-generation viral vectors for gene therapy and gene editing applications in liver and two other tissues. Program brings new levels of momentum to LogicBio as company plans for initiation of enrollment of SUNRISE Phase I/II clinical trial in treatment of methylmalonic acidemia (MMA) and other milestones.
-
LogicBio Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
1/6/2021
LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company, today announced that president and chief executive officer Fred Chereau will present virtually at the 39 th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 4:30 pm ET . Mr. Chereau will provide an overview of com
-
Cecilia Jones Joins LogicBio Therapeutics as Chief Financial Officer
12/22/2020
LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company, today announced the appointment of Cecilia Jones as the Company's chief financial officer, effective January 11, 2021.
-
BioSpace Movers & Shakers, Dec. 18
12/18/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
LogicBio Therapeutics names Daphne Karydas and Jeff Goater to Board of Directors
12/14/2020
LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company developing therapies based on advanced gene editing technology and next-generation synthetic capsids, today announced that Daphne Karydas and Jeff Goater have been appointed to the Company's board of directors.